These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18666438)

  • 1. Different assessments of immunohistochemically stained Ki-67 and hTERT in glioblastoma multiforme yield variable results: a study with reference to survival prognosis.
    Persson A; Englund E
    Clin Neuropathol; 2008; 27(4):224-33. PubMed ID: 18666438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.
    Tsidulko AY; Kazanskaya GM; Kostromskaya DV; Aidagulova SV; Kiselev RS; Volkov AM; Kobozev VV; Gaitan AS; Krivoshapkin AL; Grigorieva EV
    Tumour Biol; 2017 Sep; 39(9):1010428317724282. PubMed ID: 28945172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal stromal tumors - quantitative detection of the Ki-67, TPX2, TOP2A, and hTERT telomerase subunit mRNA levels to determine proliferation activity and a potential for aggressive biological behavior.
    Kalfusova A; Hilska I; Krskova L; Kalinova M; Linke Z; Kodet R
    Neoplasma; 2016; 63(3):484-92. PubMed ID: 26952515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of astrocytomas and meningiomas: an evaluation in vitro.
    Maes L; Kalala JP; Cornelissen M; de Ridder L
    Cell Prolif; 2007 Feb; 40(1):14-23. PubMed ID: 17227292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki-67 labeling index in glioblastoma; does it really matter?
    Alkhaibary A; Alassiri AH; AlSufiani F; Alharbi MA
    Hematol Oncol Stem Cell Ther; 2019 Jun; 12(2):82-88. PubMed ID: 30552865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme.
    Chang CY; Li MC; Liao SL; Huang YL; Shen CC; Pan HC
    J Clin Neurosci; 2005 Nov; 12(8):930-3. PubMed ID: 16326273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of Ki-67 Index with Volumetric Segmentation and its Value as a Prognostic Marker in Glioblastoma.
    Henker C; Kriesen T; Schneider B; Glass Ä; Scherer M; Langner S; Erbersdobler A; Piek J
    World Neurosurg; 2019 May; 125():e1093-e1103. PubMed ID: 30790732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of p53 in glioblastoma multiforme cells: relationship to survival, proliferation and glycosylation.
    Ehrmann J; Kolár Z; Kala M; Vojtĕsek B; Komenda S
    Cesk Patol; 1995 Aug; 31(3):87-91. PubMed ID: 9444787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance.
    Alonso MM; Fueyo J; Shay JW; Aldape KD; Jiang H; Lee OH; Johnson DG; Xu J; Kondo Y; Kanzawa T; Kyo S; Bekele BN; Zhou X; Nigro J; McDonald JM; Yung WK; Gomez-Manzano C
    J Natl Cancer Inst; 2005 Nov; 97(21):1589-600. PubMed ID: 16264179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of ALDH1, EZH2 and Ki-67 in Astrocytic Gliomas.
    Ahmed S; Rashed H; Hegazy A; Mohamed AM; Elmesallamy W
    Turk Patoloji Derg; 2016; 32(2):70-81. PubMed ID: 27136105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cut-point for Ki-67 proliferation index as a prognostic marker for glioblastoma.
    Wong E; Nahar N; Hau E; Varikatt W; Gebski V; Ng T; Jayamohan J; Sundaresan P
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):5-9. PubMed ID: 29336530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression and significance of hTERT, c-myc and Ki-67 in hepatocellular carcinoma].
    Fang YW
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Apr; 25(4):338-40. PubMed ID: 19351506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High IFIT1 expression predicts improved clinical outcome, and IFIT1 along with MGMT more accurately predicts prognosis in newly diagnosed glioblastoma.
    Zhang JF; Chen Y; Lin GS; Zhang JD; Tang WL; Huang JH; Chen JS; Wang XF; Lin ZX
    Hum Pathol; 2016 Jun; 52():136-44. PubMed ID: 26980050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No prognostic impact of survivin expression in glioblastoma.
    Preusser M; Gelpi E; Matej R; Marosi C; Dieckmann K; Rössler K; Budka H; Hainfellner JA
    Acta Neuropathol; 2005 May; 109(5):534-8. PubMed ID: 15843906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature.
    Reavey-Cantwell JF; Haroun RI; Zahurak M; Clatterbuck RE; Parker RJ; Mehta R; Fruehauf JP; Brem H
    J Neurooncol; 2001 Dec; 55(3):195-204. PubMed ID: 11859975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of serum levels and tissue expression of two genes IGFBP-2 and IGFBP-3 act as potential biomarker for predicting the progression and survival in patients with glioblastoma multiforme.
    Abdolhoseinpour H; Mehrabi F; Shahraki K; Khoshnood RJ; Masoumi B; Yahaghi E; Goudarzi PK
    J Neurol Sci; 2016 Jul; 366():202-206. PubMed ID: 27288807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
    Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
    Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.
    Pollack IF; Hamilton RL; Burnham J; Holmes EJ; Finkelstein SD; Sposto R; Yates AJ; Boyett JM; Finlay JL
    Neurosurgery; 2002 Jun; 50(6):1238-44; discussion 1244-5. PubMed ID: 12015841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo.
    Cabuy E; de Ridder L
    Virchows Arch; 2001 Aug; 439(2):176-84. PubMed ID: 11561758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.